Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study)

Shen, Lin; Li, Jin; Xu, Jianming; Pan, Hongming; Dai, Guanghai; Qin, Shukui; Wang, Liwei; Wang, Jinwan; Yang, Zhenzhou; Shu, Yongqian; Xu, Rui‐Hua; Chen, Lei; Liu, Yunpeng; Yu, Shiying; Bu, Lilian; Piao, Yongzhe

doi:10.1007/s10120-014-0351-5

Public

Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study)

Published in Gastric Cancer • Feb 20, 2014

Authors:

Lin Shen

Jin Li

Jianming Xu

Abstract

BACKGROUND: In the AVAGAST study, fluoropyrimidine and cisplatin plus bevacizumab did not significantly improve overall survival (OS) versus fluoropyrimidine and cisplatin plus placebo in patients with advanced gastric cancer. Geographic differences in efficacy were observed in AVAGAST, but the stud...

Subject

Medicine

Bevacizumab

Capecitabine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!